HRP20200968T1 - Metoda liječenja i sastavi koji sadrže dualni pi3k delta-gama kinaza inhibitor i kortikosteroid - Google Patents
Metoda liječenja i sastavi koji sadrže dualni pi3k delta-gama kinaza inhibitor i kortikosteroid Download PDFInfo
- Publication number
- HRP20200968T1 HRP20200968T1 HRP20200968TT HRP20200968T HRP20200968T1 HR P20200968 T1 HRP20200968 T1 HR P20200968T1 HR P20200968T T HRP20200968T T HR P20200968TT HR P20200968 T HRP20200968 T HR P20200968T HR P20200968 T1 HRP20200968 T1 HR P20200968T1
- Authority
- HR
- Croatia
- Prior art keywords
- corticosteroid
- pi3k delta
- dual pi3k
- gamma inhibitor
- disease
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title claims 31
- 230000009977 dual effect Effects 0.000 title claims 27
- 238000000034 method Methods 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title claims 2
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 27
- 108091007960 PI3Ks Proteins 0.000 claims 27
- 239000003112 inhibitor Substances 0.000 claims 27
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 14
- 208000027866 inflammatory disease Diseases 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 9
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 8
- 229960003957 dexamethasone Drugs 0.000 claims 8
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 8
- 208000023275 Autoimmune disease Diseases 0.000 claims 7
- 230000001363 autoimmune Effects 0.000 claims 7
- 229960002537 betamethasone Drugs 0.000 claims 7
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 claims 7
- 229960000890 hydrocortisone Drugs 0.000 claims 7
- 230000000241 respiratory effect Effects 0.000 claims 7
- 208000023504 respiratory system disease Diseases 0.000 claims 7
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 6
- 201000004624 Dermatitis Diseases 0.000 claims 6
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 6
- 229960004436 budesonide Drugs 0.000 claims 6
- 229960002714 fluticasone Drugs 0.000 claims 6
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 6
- 229960004584 methylprednisolone Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 229960005205 prednisolone Drugs 0.000 claims 6
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 6
- 229960004618 prednisone Drugs 0.000 claims 6
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 6
- 229960005294 triamcinolone Drugs 0.000 claims 6
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 6
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 4
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 4
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 4
- 206010039085 Rhinitis allergic Diseases 0.000 claims 4
- 201000010105 allergic rhinitis Diseases 0.000 claims 4
- 208000006673 asthma Diseases 0.000 claims 4
- 201000008937 atopic dermatitis Diseases 0.000 claims 4
- 229960004544 cortisone Drugs 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 4
- -1 tipredan Chemical compound 0.000 claims 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 3
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 3
- 201000002481 Myositis Diseases 0.000 claims 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 3
- 208000001132 Osteoporosis Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 206010039710 Scleroderma Diseases 0.000 claims 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 3
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 3
- 206010046851 Uveitis Diseases 0.000 claims 3
- 206010046914 Vaginal infection Diseases 0.000 claims 3
- 201000008100 Vaginitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 3
- 208000010668 atopic eczema Diseases 0.000 claims 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 3
- 210000001185 bone marrow Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 201000001981 dermatomyositis Diseases 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 208000006454 hepatitis Diseases 0.000 claims 3
- 231100000283 hepatitis Toxicity 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 201000006417 multiple sclerosis Diseases 0.000 claims 3
- 206010028417 myasthenia gravis Diseases 0.000 claims 3
- 210000000056 organ Anatomy 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 206010043778 thyroiditis Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 238000002054 transplantation Methods 0.000 claims 3
- QTQGHKVYLQBJLO-UHFFFAOYSA-N 4-methylbenzenesulfonate;(4-methyl-1-oxo-1-phenylmethoxypentan-2-yl)azanium Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC(C)CC(N)C(=O)OCC1=CC=CC=C1 QTQGHKVYLQBJLO-UHFFFAOYSA-N 0.000 claims 2
- XBGQGAPUUJJOTA-KWLUMGGGSA-N 4b52439y33 Chemical compound O.C([C@@H]1C2)C3=CC=CC=C3C[C@@]1(C(=O)CO)[C@]1(C)[C@@H]2[C@H](CCC=2[C@@]3(C=CC(=O)C=2)C)[C@]3(F)[C@@H](O)C1 XBGQGAPUUJJOTA-KWLUMGGGSA-N 0.000 claims 2
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 2
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 2
- DRSFVGQMPYTGJY-GNSLJVCWSA-N Deprodone propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O DRSFVGQMPYTGJY-GNSLJVCWSA-N 0.000 claims 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 claims 2
- YCISZOVUHXIOFY-HKXOFBAYSA-N Halopredone acetate Chemical compound C1([C@H](F)C2)=CC(=O)C(Br)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@](OC(C)=O)(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O YCISZOVUHXIOFY-HKXOFBAYSA-N 0.000 claims 2
- FOGXJPFPZOHSQS-AYVLZSQQSA-N Hydrocortisone butyrate propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O FOGXJPFPZOHSQS-AYVLZSQQSA-N 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- SBQAKZYUNWNIRL-WIPKXTQKSA-N Prednisolone farnesylate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)/C=C(C)/CC/C=C(C)/CCC=C(C)C)(O)[C@@]1(C)C[C@@H]2O SBQAKZYUNWNIRL-WIPKXTQKSA-N 0.000 claims 2
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 2
- 229960001102 betamethasone dipropionate Drugs 0.000 claims 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 claims 2
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 claims 2
- 229960003728 ciclesonide Drugs 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 229960001357 clocortolone pivalate Drugs 0.000 claims 2
- SXYZQZLHAIHKKY-GSTUPEFVSA-N clocortolone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(Cl)[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)COC(=O)C(C)(C)C)[C@@]2(C)C[C@@H]1O SXYZQZLHAIHKKY-GSTUPEFVSA-N 0.000 claims 2
- 229960001334 corticosteroids Drugs 0.000 claims 2
- 229960001145 deflazacort Drugs 0.000 claims 2
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 claims 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 claims 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 2
- 229960001347 fluocinolone acetonide Drugs 0.000 claims 2
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 claims 2
- 229960000785 fluocinonide Drugs 0.000 claims 2
- 229960000289 fluticasone propionate Drugs 0.000 claims 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims 2
- 229960002475 halometasone Drugs 0.000 claims 2
- GGXMRPUKBWXVHE-MIHLVHIWSA-N halometasone Chemical compound C1([C@@H](F)C2)=CC(=O)C(Cl)=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O GGXMRPUKBWXVHE-MIHLVHIWSA-N 0.000 claims 2
- 229950004611 halopredone acetate Drugs 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 229960002453 hydrocortisone aceponate Drugs 0.000 claims 2
- MFBMYAOAMQLLPK-FZNHGJLXSA-N hydrocortisone aceponate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]1(C)C[C@@H]2O MFBMYAOAMQLLPK-FZNHGJLXSA-N 0.000 claims 2
- 229960002846 hydrocortisone probutate Drugs 0.000 claims 2
- 229960001401 hydrocortisone sodium succinate Drugs 0.000 claims 2
- 229960003744 loteprednol etabonate Drugs 0.000 claims 2
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 claims 2
- 229960002037 methylprednisolone aceponate Drugs 0.000 claims 2
- DALKLAYLIPSCQL-YPYQNWSCSA-N methylprednisolone aceponate Chemical compound C1([C@@H](C)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CC)[C@@]2(C)C[C@@H]1O DALKLAYLIPSCQL-YPYQNWSCSA-N 0.000 claims 2
- 229950010796 methylprednisolone suleptanate Drugs 0.000 claims 2
- CDMLLMOLWUKNEK-AOHDELFNSA-M methylprednisolone suleptanate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCCCCCC(=O)N(C)CCS([O-])(=O)=O)CC[C@H]21 CDMLLMOLWUKNEK-AOHDELFNSA-M 0.000 claims 2
- 229960002744 mometasone furoate Drugs 0.000 claims 2
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims 2
- 229950005486 naflocort Drugs 0.000 claims 2
- 229960002794 prednicarbate Drugs 0.000 claims 2
- FNPXMHRZILFCKX-KAJVQRHHSA-N prednicarbate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)CC)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O FNPXMHRZILFCKX-KAJVQRHHSA-N 0.000 claims 2
- 229950011084 prednisolone farnesylate Drugs 0.000 claims 2
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 claims 2
- 229960002943 prednisolone sodium phosphate Drugs 0.000 claims 2
- 229960001487 rimexolone Drugs 0.000 claims 2
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 claims 2
- 229960002117 triamcinolone acetonide Drugs 0.000 claims 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims 2
- 229950008396 ulobetasol propionate Drugs 0.000 claims 2
- BDSYKGHYMJNPAB-LICBFIPMSA-N ulobetasol propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]2(C)C[C@@H]1O BDSYKGHYMJNPAB-LICBFIPMSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- VXOWJCTXWVWLLC-REGDIAEZSA-N betamethasone butyrate propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CCC)[C@@]1(C)C[C@@H]2O VXOWJCTXWVWLLC-REGDIAEZSA-N 0.000 claims 1
- 229950008408 betamethasone butyrate propionate Drugs 0.000 claims 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960001067 hydrocortisone acetate Drugs 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 208000037916 non-allergic rhinitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
Claims (20)
1. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu u liječenju autoimune, respiratorne i/ili upalne bolesti ili stanja, pri čemu metoda uključuje davanje subjektu kojem je to potrebna terapijski učinkovita količina (i) dualni PI3K delta i gama inhibitora, i (ii) kortikosteroida, naznačeno time je da dualni PI3K delta i gama inhibitor spoj formule A:
[image]
ili njegova farmaceutski prihvatljiva sol.
2. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno patentnom zahtjevu 1, naznačeno time da je kortikosteroid odabran iz skupine koja sadrži deksametazon, betametazon, prednizolon, metil prednizolon, prednizon, hidrokortizon, flutikazon, triamcinolon, budezonid ili kortizon prednizolon, metilprednizolon, naflokort, deflazakort, halopredon acetat, budezonid, beklometazon dipropionat, hidrokortizon, triamcinolon acetonid, fluocinolon acetonid, fluocinonid, klokortolon pivalat, metilprednizolon aceponat, deksametazon palmitoat, tipredan, hidrokortizon aceponat, prednikarbat, alklometazon dipropionat, halometazon, metilprednizolon suleptanat, mometazon furoat, rimekzolon, prednizolon farnesilat, ciklezonid, deprodon propionat, flutikazon propionat, halobetazol propionata loteprednol etabonat, betametazon butirat propionata flunizolida prednizon, deksametazon natrij fosfat, triamcinolon, betametazon 17-valerat, betametazon, betametazon dipropionat, hidrokortizon acetat, hidrokortizon natrij sukcinat, prednizolon natrij fosfat, hidrokortizon probutat, i njihovih farmaceutski prihvatljive soli.
3. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno patentnom zahtjevu 1 ili patentnom zahtjevu 2, naznačeno time da je kortikosteroid izabran iz skupine koja sadrži deksametazon, betametazon, prednizolon, metil prednizolon, prednizon, hidrokortizon, flutikazon, triamcinolon, budezonid, kortizon, i njihovih farmaceutski prihvatljive soli.
4. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 3, naznačeno time da je kortikosteroid izabran od deksametazona, flutikazona, i njihovih farmaceutski prihvatljivih soli.
5. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time da terapijski učinkovita količina (i) dualnog PI3K delta i gama inhibitora, i terapeutski efikasna količina (ii) kortikosteroida daje se istovremeno kao kombinirana formulacija.
6. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 5, naznačeno time da terapijski učinkovita (i) dualnog PI3K delta i gama inhibitora, i terapijski učinkovita količina (ii) kortikosteroida su primijenjene sekvencijalno.
7. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno patentnom zahtjevu 6, naznačeno time da terapijski učinkovita količina kortikosteroida je primijenjena prije učinkovite količine dualnog PI3K delta i gama inhibitora.
8. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 7, naznačeno time da terapijski učinkovita količina PI3K delta i gama inhibitora je primijenjena dva puta dnevno do jedanput svaka tri tjedna, i terapijski učinkovita količina kortikosteroida je primijenjena dva puta dnevno do jedanput svaka tri tjedna.
9. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 to 8, naznačeno time da autoimuna, respiratorna i/ili upalna bolest ili stanje je odabrano iz skupine koja se sastoji od astme, kronične opstruktivne bolesti pluća, reumatoidnog artritisa, upalne bolesti crijeva, glomerulonefritisa, neuro upalne bolesti, multipla skleroze, uveitisa, psorijaze, artritisa, vaskulitisa, dermatitisa, osteoartritisa, upalne bolesti mišića, alergijskog rinitisa, vaginitisa, intersticijalnog cistitisa, skleroderme, osteoporoze, ekcema, odbacivanja alogene ili ksenogene transplantacije grafta (organa, koštane srži, matičnih stanica i drugih stanica i tkiva), bolesti graft-protiv-domaćina, eritemskog lupusa, upalne bolesti, dijabetesa Tipa I, plućne fibroze, dermatomiozitisa, Sjogrenov sindroma, tiroiditisa, miastenije gravis, autoimune hemolitičke anemije, cistične fibroze, idiopatske plućne fibroze (IPF), kroničnog relapsnog hepatitisa, primarne bilijarne ciroze, alergijskog konjuktivitisa, atopijskog dermatitisa, i njihovih kombinacija.
10. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 9, naznačeno time da autoimuna, respiratorna i/ili upalna bolest ili stanje je odabrano iz skupine sastavljene od astme, alergijskog rinitisa, nealergijskog rinitisa, reumatoidnog artritisa, kronične opstruktivne plućne bolesti, idiopatske plućne fibroze (IPF) i atopijskog dermatitisa.
11. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 10, naznačeno time da je svaki od dualnog PI3K delta i gama inhibitora i kortikosteroida primjenjen u količini u omjeru od oko 0.01 mg do oko 1000 mg.
12. Dualni PI3K delta i gama inhibitor i kortikosteroid za uporabu sukladno bilo kojem od patentnih zahtjeva 1 do 11, naznačeno time da dualni PI3K delta i gama inhibitor i kortikosteroid su primjenjeni u omjeru od oko 1:100 do oko 100:1 po težini.
13. Farmaceutski pripravak koji sadrži (i) dualni PI3K delta i gama inhibitor, (ii) kortikosteroid, i (iii) izborno, farmaceutski prihvatljiv nosač, sredstvo za klizanje, otapalo, ili ekscipijens;
naznačeno time da je dualni PI3K delta i gama inhibitor spoj formule A:
[image]
ili njegova farmaceutski prihvatljiva sol.
14. Farmaceutski sastav sukladno patentnom zahtjevu 13, naznačeno time da kortikosteroid je odabran iz skupine sastavljene od deksametazona, betametazona, prednizolona, metil prednizolona, prednizona, hidrokortizona, flutikazona, triamcinolona, budezonida ili kortizon prednizolona, metilprednizolona, naflokorta, deflazakorta, halopredon acetata, budezonida, beklometazon dipropionata, hidrokortizona, triamcinolon acetonida, fluocinolon acetonida, fluocinonida, klokortolon pivalata, metilprednizolon aceponata, deksametazon palmitoata, tipredana, hidrokortizon aceponata, prednikarbata, alklometazon dipropionata, halometazona, metilprednizolon suleptanata, mometazon furoata, rimekzolona, prednizolon farnesilata, ciklezonida, deprodon propionata, flutikazon propionata, halobetazol propionata, loteprednol etabonata, betametazon butirat propionata, flunizolida, prednizona, deksametazon natrij fosfata, triamcinolona, betametazon 17-valerata, betametazona, betametazon dipropionata, hidrokortizon acetata, hidrokortizon natrij sukcinata, prednizolon natrij fosfata, hidrokortizon probutata, i njihovih farmaceutski prihvatljivih soli.
15. Farmaceutski sastav sukladno patentnom zahtjevu 13 ili patentnom zahtjevu 14, naznačeno time da je kortikosteroid odabran iz skupine sastavljene od deksametazona, betametazona, prednizolona, metil prednizolona, prednizona, hidrokortizona, flutikazona, triamcinolona, budezonida, kortizona, i njihovih farmaceutski prihvatljivih soli.
16. Farmaceutski sastav sukladno bilo kojem od patentnih zahtjeva 13 do 15, naznačeno time da je kortikosteroid odabran iz deksametazona, flutikazona, i njihovih farmaceutski prihvatljivih soli.
17. Farmaceutski sastav sukladno bilo kojem od patentnih zahtjeva 13 do 16, naznačeno time da pripravak sadrži oko 0.01 mg do oko 1000 mg dualni PI3K delta i gama inhibitora i oko 0.01 mg do oko 1000 mg kortikosteroida.
18. Farmaceutski sastav sukladno bilo kojem od patentnih zahtjeva 13 do 17, za uporabu u liječenju autoimune, respiratorne i/ili upalne bolesti ili stanja odabranog iz skupine sastavljene od astme, kronične opstruktivne plućne bolesti, reumatoidnog artritisa, upalne bolesti crijeva, glomerulonefritisa, neuro upalnih bolesti, multipla skleroze, uveitisa, psorijaze, artritisa, vaskulitisa, dermatitisa, osteoartritisa, upalne bolesti mišića, alergijskog rinitisa, vaginitisa, intersticijalnog cistitisa, skleroderme, osteoporoze, ekcema, odbacivanja alogene ili ksenogene transplantacije grafta (organa, koštane srži, matičnih stanica i drugih stanica i tkiva), bolesti graft-protiv-domaćina, eritemskog lupusa, upalne bolesti, dijabetesa Tipa I, plućne fibroze, dermatomiozitisa, Sjogren sindroma, tiroiditisa (npr. Hashimoto i autoimuni tiroiditis), miastenije gravis, autoimune hemolitičke anemije, cistične fibroze, idiopatske plućne fibroze (IPF), kroničnog relapsnog hepatitisa, primarne bilijarne ciroze, alergijskog konjuktivitisa, atopijskog dermatitisa, i njihovih kombinacija.
19. Komplet za uporabu u liječenju autoimune, respiratorne i/ili upalne bolesti ili stanja, pri čemu komplet sadrži:
(i) dualni PI3K delta i gama inhibitor, i (ii) kortikosteroid, ili njihovu farmaceutski prihvatljivu sol, ili kao jedan farmaceutski pripravak ili u zasebnim farmaceutskim pripravcima,
(ii) opcionalno, upute za liječenje autoimune, respiratorne i/ili upalne bolesti ili stanja s dualnim PI3K delta i gama inhibitorom i kortikosteroidom i
(iii) izborno, spremnik za smještanje farmaceutskog pripravka ili farmaceutskih pripravaka: naznačeno time da je dualni PI3K delta i gama inhibitor spoj formule A:
[image]
20. Komplet za uporabu sukladno patentnom zahtjevu 19, naznačeno time da dualni PI3K delta i gama inhibitor i kortikosteroid su za uporabu u liječenju autoimune, respiratorne i/ili upalne bolesti ili stanja odabranog iz astme, kronične opstruktivne plućne bolesti, reumatoidnog artritisa, upalne bolesti crijeva, glomerulonefritisa, neuro upalnih bolesti, multipla skleroze, uveitisa, psorijaze, artritisa, vaskulitisa, dermatitisa, osteoartritisa, upalne bolesti mišića, alergijskog rinitisa, vaginitisa, intersticijalnog cistitisa, skleroderme, osteoporoze, ekcema, odbacivanja alogene ili ksenogene transplantacije grafta (organa, koštane srži, matičnih stanica i drugih stanica i tkiva), bolesti graft-protiv-domaćina, eritemskog lupusa, upalne bolesti, dijabetesa Tipa I, plućne fibroze, dermatomiozitisa, Sjogren sindroma, tiroiditisa (npr., Hashimoto i autoimuni tiroiditis), miastenije gravis, autoimune hemolitičke anemije, cistične fibroze, idiopatske plućne fibroze (IPF), kroničnog relapsnog hepatitisa, primarne bilijarne ciroze, alergijskog konjuktivitisa i atopijskog dermatitisa.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4287CH2014 | 2014-09-03 | ||
| PCT/IB2015/056720 WO2016035032A1 (en) | 2014-09-03 | 2015-09-03 | Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid |
| EP15774713.0A EP3188759B1 (en) | 2014-09-03 | 2015-09-03 | Method of treatment and compositions comprising a dual pi3k delta-gamma kinase inhibitor and a corticosteroid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200968T1 true HRP20200968T1 (hr) | 2020-10-16 |
Family
ID=54249540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200968TT HRP20200968T1 (hr) | 2014-09-03 | 2020-06-18 | Metoda liječenja i sastavi koji sadrže dualni pi3k delta-gama kinaza inhibitor i kortikosteroid |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US10786504B2 (hr) |
| EP (2) | EP3188759B1 (hr) |
| JP (3) | JP6559775B2 (hr) |
| KR (1) | KR20170044203A (hr) |
| CN (2) | CN113332439A (hr) |
| AU (2) | AU2015310545B2 (hr) |
| BR (1) | BR112017004163A2 (hr) |
| CA (1) | CA2958988A1 (hr) |
| CL (1) | CL2017000512A1 (hr) |
| CY (1) | CY1123075T1 (hr) |
| DK (1) | DK3188759T3 (hr) |
| EA (2) | EA202092492A1 (hr) |
| ES (1) | ES2802202T3 (hr) |
| HR (1) | HRP20200968T1 (hr) |
| HU (1) | HUE049480T2 (hr) |
| IL (2) | IL250918B (hr) |
| LT (1) | LT3188759T (hr) |
| MX (2) | MX2017002878A (hr) |
| PH (1) | PH12017500378A1 (hr) |
| PL (1) | PL3188759T3 (hr) |
| PT (1) | PT3188759T (hr) |
| RS (1) | RS60450B1 (hr) |
| SG (2) | SG11201701499YA (hr) |
| SI (1) | SI3188759T1 (hr) |
| WO (1) | WO2016035032A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116492351B (zh) * | 2023-03-13 | 2024-03-12 | 香港大学深圳医院 | 氯替泼诺在制备治疗早发性卵巢功能不全及卵巢响应匮乏药物中的应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4018774A (en) | 1976-02-13 | 1977-04-19 | E. R. Squibb & Sons, Inc. | Steroidal [16α,17-d]isoxazolidines |
| SE8106165L (sv) | 1981-10-19 | 1983-04-20 | Atlas Copco Ab | Forfarande for bergbultning och bergbult |
| GB0415747D0 (en) | 2004-07-14 | 2004-08-18 | Novartis Ag | Organic compounds |
| UA119314C2 (uk) | 2008-01-04 | 2019-06-10 | Інтеллікіне Ллк | Спосіб отримання похідних ізохінолінону (варіанти) |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US11058699B2 (en) | 2008-07-01 | 2021-07-13 | Wisconsin Alumni Research Foundation | Method and compositions for inhibition of double stranded DNA viruses |
| EP2411003A4 (en) * | 2009-03-24 | 2012-10-17 | Univ Singapore | USE OF ARTEMISININE DERIVATIVES IN THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE BRONCHO-PNEUMOPATHY (COPD) |
| AU2010294598B2 (en) | 2009-09-11 | 2016-09-01 | Chiesi Farmaceutici S.P.A. | Pregnane derivatives condensed in the 16, 17 position with an n-substituted isoxazolidine ring as anti-inflammatory agents |
| AU2010316780B2 (en) * | 2009-11-05 | 2015-07-16 | Rhizen Pharmaceuticals Sa | Novel benzopyran kinase modulators |
| AU2011210640A1 (en) * | 2010-01-28 | 2012-06-07 | The Johns Hopkins University | Compositions and methods for reversing corticosteroid resistance or treating respiratory infections |
| US10231976B2 (en) * | 2010-02-08 | 2019-03-19 | Prairie Pharmaceuticals LLC | Methods for the use of progestogen as a glucocorticoid sensitizer |
| SG10201600179RA (en) | 2011-01-10 | 2016-02-26 | Infinity Pharmaceuticals Inc | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| KR101956937B1 (ko) | 2011-03-15 | 2019-03-11 | 키에시 파르마슈티시 엣스. 피. 에이. | 이속사졸리딘 유도체 |
| ES2710874T3 (es) * | 2011-05-04 | 2019-04-29 | Rhizen Pharmaceuticals S A | Compuestos novedosos como moduladores de proteína cinasas |
| WO2013173901A1 (en) | 2012-05-22 | 2013-11-28 | Atlas Copco Canada Inc. | Rock bolt and method of installing a rock bolt |
| CN111904962A (zh) * | 2012-11-08 | 2020-11-10 | 理森制药股份公司 | 含有PDE4抑制剂和PI3 δ或双重PI3 δ-γ激酶抑制剂的药物组合物 |
| CN204282361U (zh) | 2014-12-11 | 2015-04-22 | 湖南科技大学 | 一种带钢丝网的软土地基充气锚杆 |
-
2015
- 2015-09-03 JP JP2017512375A patent/JP6559775B2/ja not_active Expired - Fee Related
- 2015-09-03 EA EA202092492A patent/EA202092492A1/ru unknown
- 2015-09-03 SG SG11201701499YA patent/SG11201701499YA/en unknown
- 2015-09-03 CA CA2958988A patent/CA2958988A1/en not_active Abandoned
- 2015-09-03 HU HUE15774713A patent/HUE049480T2/hu unknown
- 2015-09-03 WO PCT/IB2015/056720 patent/WO2016035032A1/en active Application Filing
- 2015-09-03 CN CN202110658421.3A patent/CN113332439A/zh active Pending
- 2015-09-03 PT PT157747130T patent/PT3188759T/pt unknown
- 2015-09-03 ES ES15774713T patent/ES2802202T3/es active Active
- 2015-09-03 RS RS20200736A patent/RS60450B1/sr unknown
- 2015-09-03 AU AU2015310545A patent/AU2015310545B2/en not_active Ceased
- 2015-09-03 PL PL15774713T patent/PL3188759T3/pl unknown
- 2015-09-03 CN CN201580052216.5A patent/CN106714842B/zh not_active Expired - Fee Related
- 2015-09-03 US US15/508,429 patent/US10786504B2/en active Active
- 2015-09-03 KR KR1020177008971A patent/KR20170044203A/ko not_active Application Discontinuation
- 2015-09-03 LT LTEP15774713.0T patent/LT3188759T/lt unknown
- 2015-09-03 BR BR112017004163A patent/BR112017004163A2/pt not_active Application Discontinuation
- 2015-09-03 SG SG10202100596SA patent/SG10202100596SA/en unknown
- 2015-09-03 DK DK15774713.0T patent/DK3188759T3/da active
- 2015-09-03 EA EA201790379A patent/EA038527B1/ru unknown
- 2015-09-03 MX MX2017002878A patent/MX2017002878A/es active IP Right Grant
- 2015-09-03 EP EP15774713.0A patent/EP3188759B1/en active Active
- 2015-09-03 EP EP20166664.1A patent/EP3701950A1/en not_active Withdrawn
- 2015-09-03 SI SI201531258T patent/SI3188759T1/sl unknown
-
2017
- 2017-02-28 PH PH12017500378A patent/PH12017500378A1/en unknown
- 2017-03-02 IL IL250918A patent/IL250918B/en active IP Right Grant
- 2017-03-03 MX MX2020011472A patent/MX2020011472A/es unknown
- 2017-03-03 CL CL2017000512A patent/CL2017000512A1/es unknown
-
2019
- 2019-07-17 JP JP2019131860A patent/JP2019172708A/ja active Pending
-
2020
- 2020-06-18 HR HRP20200968TT patent/HRP20200968T1/hr unknown
- 2020-06-23 CY CY20201100575T patent/CY1123075T1/el unknown
- 2020-08-21 US US16/999,825 patent/US20210030757A1/en not_active Abandoned
-
2021
- 2021-01-06 AU AU2021200051A patent/AU2021200051A1/en not_active Abandoned
- 2021-02-07 IL IL280686A patent/IL280686A/en unknown
- 2021-09-24 JP JP2021155711A patent/JP2021191804A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016101363A (ru) | Способ лечения заболеваний, связанных с глюкокортикоидной нечувствительностью | |
| AU2021201649A1 (en) | Methods and compositions for treating cancer | |
| EP2456781B1 (de) | 17-hydroxy-17-pentafluorethyl-estra-4,9 (10)-dien-11-acyloxyalkylenphenyl-derivate, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von krankheiten | |
| CA2590404A1 (en) | Treatment screening methods | |
| HRP20100104T1 (hr) | Kombinacije koje sadrže antimuskarinska sredstva i kortikosteroide | |
| RS53329B (en) | PROCEDURE AND MIXTURE FOR TREATMENT OF INFLAMMATORY DISORDERS | |
| JP2008297310A5 (hr) | ||
| HRP20200968T1 (hr) | Metoda liječenja i sastavi koji sadrže dualni pi3k delta-gama kinaza inhibitor i kortikosteroid | |
| RU2012149459A (ru) | Способ обработки частиц активных фармацевтических ингредиентов | |
| JP6501774B2 (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| JP2017197569A5 (hr) | ||
| RU2014113906A (ru) | Терапевтическое применение эктоина | |
| HRP20160050T1 (hr) | Derivati estra-1,3,5(10),16-tetraen-3-karboksamida, postupak njihove priprave, farmaceutski pripravci koji ih sadrže i na njihova upotreba za proizvodnju lijekova | |
| US8829024B2 (en) | Combination steroid and glucocorticoid receptor antagonist therapy | |
| HRP20201789T1 (hr) | Antiproliferativni spojevi, te njihovi farmaceutski pripravci i uporabe | |
| JP2016510012A (ja) | Ｍａｂａ化合物およびコルチコステロイドを含む組合せ剤 | |
| RU2015145135A (ru) | Лечение воспалительных расстройств | |
| EP2701744A1 (en) | Combination therapy | |
| WO2015156219A1 (ja) | 抗真菌剤とステロイドとを含有する医薬組成物 | |
| CN101938996A (zh) | 用于治疗免疫炎症性紊乱的治疗方案 | |
| US20120309722A1 (en) | Therapeutic regimens for the treatment of immunoinflammatory disorders | |
| HRP20120678T1 (hr) | Farmaceutski pripravci zasnovani na antagonistima kininskog b2 receptora i kortikosteroidima te njihova upotreba | |
| RU2013148786A (ru) | Улучшенный состав суспензии кортикостероида для ингаляционного введения | |
| US20090111782A1 (en) | Composition and methods relating to glucocorticoid receptor-alpha and peroxisome proliferator-activated receptors |